© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Grzegorz S. Nowakowski, MD, reviews the case of a 76-year-old woman with DLBCL and discusses the available treatment options, including options after relapse.
June 29th 2022
Grzegorz S. Nowakowski, MD, presents the case of a woman with relapsed DLBLC and provides his initial impressions.
July 13th 2022
A discussion on the clinical factors that put patients at risk of having relapsed DLBCL.
Dr Grzegorz S. Nowakowski reviews the currently available second-line treatment options for transplant-ineligible R/R DLBCL.
An explanation of the design, efficacy, and adverse events of L-MIND, a trial investigating a combination treatment for R/R DLBCL.
July 14th 2022
Grzegorz S. Nowakowski, MD, reviews the approved further-line treatment options for relapsed DLBCL.
Dr Grzegorz S. Nowakowski muses on the unmet needs of patients with DLBCL and the emerging treatment options he looks forward to.
An expert describes factors for consideration when choosing a second-line treatment for relapsed DLBCL.